At Axis-Shield, innovation is fundamental to our business. There is an increasing need for new diagnostic tests in many disease areas.
We are continually striving to develop improved methods to diagnose disease, employing both in-house expertise and our links with external centres of excellence.
Identifying these diseases quickly and efficiently can be vital in maintaining a patient's quality of life.
New drug treatments are evolving alongside innovative diagnostics, which is leading to improved patient management and monitoring of treatment efficacy.
At Axis-Shield, innovation is fundamental to our business. There is an increasing need for new diagnostic tests in many disease areas.
We are continually striving to develop improved methods to diagnose disease, employing both in-house expertise and our links with external centres of excellence.
Identifying these diseases quickly and efficiently can be vital in maintaining a patient's quality of life.
New drug treatments are evolving alongside innovative diagnostics, which is leading to improved patient management and monitoring of treatment efficacy.

Major new publication on HBP

Our new sepsis marker HBP is the subject of an important new paper which supports its use in identifying patients who are at risk of developing severe sepsis.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603368/pdf/ccm-43-2378.pdf

For more information on HBP please visit www.heparinbindingprotein.com

Axis Shield

Axis Shield main website

Major new publication on HBP